OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases

NEXT STORY
Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
PREV STORY
Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

111, Inc. to Collaborate with Lilly in Creating New Solutions for Pharmaceutical Distribution

SHANGHAI, China, Jan. 28, 2019 (GLOBE NEWSWIRE) -- 111, Inc. (NASDAQ: YI) (“111” or ...

author_avatar
NASDAQ Market News

Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Yaqrit as part of the ALIVER Consortium announces completion of first randomised controlled study of DIALIVE for ACLF at EASL’s Digital International Liver Congress

author_avatar
NASDAQ Market News